Jafarnejad A, Bathaie S Z, Nakhjavani M, Hassan M Z, Banasadegh S
Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Diabetes Metab Res Rev. 2008 Jan-Feb;24(1):64-73. doi: 10.1002/dmrr.769.
L-Lysine (L-Lys) has been known as an inhibitor of protein glycation; however, its long-term use for diabetes treatment considering different aspects of diabetic complication is not seen in the literature. In addition, the effect of L-Lys, as a chemical chaperone, was considered on protein folding and activity.
The streptozotocin-induced diabetic rats were used as a model of diabetes. Normal and diabetic rats were studied for 5 months with and without 0.1% of L-Lys in drinking water. Serum glucose, advanced glycation end product (AGEs), haemoglobin A(1C) (HbA(1c)), triglyceride, total cholesterol, HDL-cholesterol, antioxidant activity, advanced oxidation protein products, fasting insulin level and body weight were determined at 4-week intervals. Heat shock protein (HSP)70, Lecithin: cholesterol acyl transferase (LCAT) and paraoxonase activity were determined 1 week after diabetes induction (time 0), and after 3 and 5 months. The structure of glycated and normal serum albumin (Alb) in the presence and absence of L-Lys was also investigated in an in vitro study using spectrofluorometry and circular dichroism (CD).
We found that L-Lysine therapy prevented diabetic- induced increases in Glc, AGE, HbA(1c), triglyceride, total- and LDL- cholesterol, and it caused an increase in the decreased antioxidant capacity, HDL-c, HDL functionality and HSP70. L-Lys had no effect on serum insulin level. The conformation of Alb changed due to glycation and L-Lys retained it similar to the native.
L-Lys, not only as an inhibitor of glycation but also as a chemical chaperone and a protein chaperone inducer, causes effective changes in many parameters of the model animals. However, it is not enough to achieve complete improvement.
L-赖氨酸(L-Lys)一直被认为是蛋白质糖基化的抑制剂;然而,从糖尿病并发症的不同方面考虑,其在糖尿病治疗中的长期应用在文献中未见报道。此外,还研究了L-赖氨酸作为化学伴侣对蛋白质折叠和活性的影响。
将链脲佐菌素诱导的糖尿病大鼠作为糖尿病模型。正常大鼠和糖尿病大鼠在饮用含0.1% L-赖氨酸和不含L-赖氨酸的水的情况下进行5个月的研究。每隔4周测定血清葡萄糖、晚期糖基化终产物(AGEs)、糖化血红蛋白A1C(HbA1c)、甘油三酯、总胆固醇、高密度脂蛋白胆固醇、抗氧化活性、晚期氧化蛋白产物、空腹胰岛素水平和体重。在糖尿病诱导后1周(时间0)以及3个月和5个月后测定热休克蛋白(HSP)70、卵磷脂胆固醇酰基转移酶(LCAT)和对氧磷酶活性。还使用荧光光谱法和圆二色性(CD)在体外研究了在有和没有L-赖氨酸的情况下糖化和正常血清白蛋白(Alb)的结构。
我们发现,L-赖氨酸治疗可预防糖尿病引起的葡萄糖、AGE、HbA1c、甘油三酯、总胆固醇和低密度脂蛋白胆固醇的升高,并使降低的抗氧化能力、高密度脂蛋白胆固醇、高密度脂蛋白功能和HSP70增加。L-赖氨酸对血清胰岛素水平没有影响。Alb的构象因糖基化而改变,而L-赖氨酸使其保持与天然状态相似。
L-赖氨酸不仅作为糖基化抑制剂,而且作为化学伴侣和蛋白质伴侣诱导剂,可使模型动物的许多参数发生有效变化。然而,这还不足以实现完全改善。